Analysis of innovative clinical developments in the field of therapy for metastatic prostate cancer: bright results of the ASCO Congress-2022
https://doi.org/10.47619/2713-2617.zm.2022.v.3i2;72-81
Abstract
Introduction. Prostate cancer (PC), according to the results for 2019, is the second most frequently diagnosed malignant tumor in men living in the Russian Federation. There is a significant proportion of patients with advanced (III-IV stages) of prostate cancer - up to 50 %, while metastatic cancer accounts for up to 18.1 % of patients. Popularization in the Moscow City Healthcare clinical practice of innovative technologies for managing patients with metastatic castration-resistant prostate cancer (mCRPC) directly meets the goals and objectives of the Federal project aimed at increasing the life expectancy of cancer patients.
Materials and methods. The article reviews the results of clinical developments in the field of mCRPC treatment presented at The ASCO Annual Meeting, June 3-7, 2022: VISION sub-studies, TheraP study, study of the prognostic role of circulating tumor DNA (ctDNA) in the early choice of a strategy for the use of abiraterone or enzalutamide in patients with initial mCRPC - treatment naïve - status.
Results and discussion. The volume of clinical information on the results of theranostic antitumor radiation technologies implemented with the participation of prostate-specific membrane antigen (hereinafter referred to as PSMA) is growing rapidly. PSMA - mediated radio-imaging is considered as a potentially effective tool for selecting patients who are sensitive to specific therapy. When studying radionuclide therapy mediated by a ligand to PSMA (PSMA-L), the main efforts are focused on determining the optimal regimens for its clinical application. The possibility of expanding the current indications for prescribing 177Lu-PSMA-617 to patients with prostate cancer at an earlier stage is also being studied. Until final results are obtained from clinical trials that provide clear answers to open questions regarding various aspects of the application of innovative PSMA - mediated theranostic technologies, it remains very important to reach an expert consensus, within the framework of an exchange of opinions, regarding their appropriate use in various clinical situations.
About the Authors
D. A. AndreevRussian Federation
Dmitry A. Andreev – MD, PhD, Physician – Dermatovenerologist, Leading Research Fellow, Scientific-Clinical Department
9, Sharikopodshipnikovskaya str., 115088, Moscow
A. A. Zavyalov
Russian Federation
Aleksander A. Zavyalov − МD, PhD, Doctor of Medical Sciences, Professor of Oncology, Head of the Scientific – Clinical Department
9, Sharikopodshipnikovskaya str., 115088, Moscow; 23, st. Marshal Novikov, 123098, Moscow
References
1. Stilidy I. S., Gevorkyan T. G., Shpak A. G. Improving the indicators of the federal project "Fight against oncological diseases". Bulletin of Roszdravnadzor. 2021;1:46-53.
2. Kaprin A, D., Starinsky V. V., Shakhzadova A. O. eds. Malignant Neoplasms in Russia in 2019 (Morbidity and Mortality). MNIOI them. P. A. Herzen - branch of the Federal State Budgetary Institution "NMITs Radiology" of the Ministry of Health of Russia; 2020.
3. Andreev D. A., Zavyalov A. A., Govorov A. V., Kokushkin K. A., Davydovskaya M. V. Castration-resistant prostate cancer: new prospects for drug therapy. Russian medical journal. 2019;25(1):49-58. doi:10.18821/0869-2106-2019-25-1-49-58.
4. Markova A. S. Modern possibilities of drug treatment of castration-resistant prostate cancer. Oncourology. 2013;2:73-77.
5. Gallaher J., Cook L. M., Gupta S., Araujo A., Dhillon J., Park JY et al. Improving treatment strategies for patients with metastatic castrate resistant prostate cancer through personalized computational modeling. Clin Exp Metastasis. 2014;31(8):991-999. doi:10.1007/s10585-014-9674-1
6. American Society of Clinical Oncology. ASCO Annual Meeting 2022. Published 2022. Accessed June 14, 2022. https://meetings.asco.org/meetings/2022-asco-annual-meeting/288/program-guide/scheduledsessions
7. DIGITAL SCIENCE PRESS L, Armstrong AJ, Wallis JD. ASCO 2022: [68Ga]Ga-PSMA-11 PET Baseline Imaging as a Prognostic Tool for Clinical Outcomes to [177Lu]Lu-PSMA-617 in Patients With mCRPC: A VISION Substudy. Published 2022. Accessed June 15, 2022. https://www. urotoday.com/conference-highlights/asco-2022/asco-2022-prostate-cancer/137641-asco-2022-68gaga-psma-11-pet-baseline-imaging-as-a-prognostictool-for-clinical-outcomes-to-177lu-lu-psma-617-in-patients-with-mcrpc-a-vision-substudy.html
8. DIGITAL SCIENCE PRESS L, Vaishampayan N., Wallis J. D. ASCO 2022: [177Lu]Lu-PSMA-617 in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer: Prior and Concomitant Treatment Subgroup Analyses of the VISION Trial. Published 2022. Accessed June 15, 2022. https://www.urotoday.com/conference-highlights/asco-2022/asco-2022-prostate-cancer/137641-asco-2022-68gaga-psma-11-pet-baseline-imaging-as-a-prognostictool-for-clinical-outcomes-to-177lu-lu-psma-617-in-patients-with-mcrpc-a-vision-substudy.html
9. Vaishampayan N., Morris M. J., Krause B. J., Vogelzang N.J., Kendi A.T., Nordquist LT et al. [177Lu] Lu-PSMA-617 in PSMA-positive metastatic castrationresistant prostate cancer: Prior and concomitant treatment subgroup analyses of the VISION trial. J Clin Oncol. 2022;40(16\_suppl):5001. doi:10.1200/JCO.2022.40.16\_suppl.5001
10. Kuo P., Hesterman J., Rahbar K., Kendi A.T., Wei X. X, Fang B. et al. [68Ga]Ga-PSMA-11 PET baseline imaging as a prognostic tool for clinical outcomes to [177Lu]Lu-PSMA-617 in patients with mCRPC: A VISION substudy. J Clin Oncol. 2022;40(16\_suppl):5002. doi:10.1200/JCO.2022.40.16\_suppl.5002
11. Hofman M. S., Emmett L., Sandhu S., Iravani A., Joshua A.M., Goh J. C. et al. TheraP: 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castrationresistant prostate cancer (mCRPC) progressing after docetaxel—Overall survival after median follow-up of 3 years (ANZUP 1603). J Clin Oncol. 2022;40(16\_suppl):5000. doi:10.1200/JCO.2022.40.16\_suppl.5000
12. DIGITAL SCIENCE PRESS L. Hofman M., Wallis J.D. ASCO 2022: TheraP: 177Lu-PSMA-617 (LuPSMA) Versus Cabazitaxel in Metastatic Castration Resistant Prostate Cancer (McRpc) Progressing After Docetaxel–Overall Survival After Median Follow-Up of 3 Years (ANZUP 1603). Published 2022. Accessed June 20, 2022. https://www.urotoday.com/conference-highlights/asco-2022/asco-2022-prostatecancer/137642-asco-2022-therap-177lu-psma-617-lupsma-versus-cabazitaxel-in-metastatic-castrationresistant-prostate-cancer-mcrpc-progressing-afterdocetaxel-overall-survival-after
13. MEDtalks, Tolmeijer S. CtDNA als mogelijke biomarker voor de behandeling van prostaatkanker. Published 2022. Accessed June 20, 2022. https://www.medtalks.nl/asco2022-sofietolmeijer
14. Tolmeijer S.H., Boerrigter E., Schalken J.A., Geerlings M.J., van Oort I. M., van Erp N.P. et al. A Systematic Review and Meta-Analysis on the Predictive Value of Cell-Free DNA–Based Androgen Receptor Copy Number Gain in Patients With Castration-Resistant Prostate Cancer. JCO Precis Oncol. 2020;(4):714-729. doi:10.1200/PO.20.00084
15. National Library of Medicine. Optimizing Abiraterone Therapy (OPTIMUM). Published 2022. Accessed June 24, 2022. https://clinicaltrials.gov/ct2/show/NCT02426333
16. National Library of Medicine. Personalizing Enzalutamide Therapy by Understanding the Relation Between Tumor mRNAs, miRNAs and Treatment Response (ILUMINATE). Published 2022. Accessed June 24, 2022. https://clinicaltrials.gov/ct2/show/NCT02471469
17. Tolmeijer S,H., Boerrigter E., Sumiyoshi T., Ng S., Kwan E. M., Annala M. et al. On-treatment plasma ctDNA fraction and treatment outcomes in metastatic castration-resistant prostate cancer. J Clin Oncol. 2022;40(16\_suppl):5051. doi:10.1200/JCO.2022.40.16\_suppl.5051
18. Fanti S., Briganti A., Emmett L., Fizazi K., Gillessen S., Goffin K. et al. EAU-EANM Consensus Statements on the Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Patients with Prostate Cancer and with Respect to [177Lu]Lu-PSMA Radioligand Therapy. Eur Urol Oncol. Published online June 2022. doi:10.1016/j.euo.2022.05.003
19. Hartrampf P. E., Seitz A. K., Weinzierl F.X., Serfling S.E., Schirbel A., Rowe S. P. et al. Baseline clinical characteristics predict overall survival in patients undergoing radioligand therapy with [177Lu] Lu-PSMA I&T during long-term follow-up. Eur J Nucl Med Mol Imaging. Published online June 2, 2022. doi:10.1007/s00259-022-05853-2
20. Fanti S., Kunikowska J., Walz J., Witjes W., Bjartell A. EANM-EAU consensus on PSMA PET/CT in respect to radioligand therapy ([177Lu]Lu-PSMA). Eur J Nucl Med Mol Imaging. Published online June 14, 2022. doi:10.1007/s00259-022-05864-z
Review
For citations:
Andreev D.A., Zavyalov A.A. Analysis of innovative clinical developments in the field of therapy for metastatic prostate cancer: bright results of the ASCO Congress-2022. City Healthcare. 2022;3(2):56-65. (In Russ.) https://doi.org/10.47619/2713-2617.zm.2022.v.3i2;72-81